Simvastatin and Recombinant Antagonist of Receptors of Interleukin-1 Modulate Toll-like Receptors in Experimental Acute Ileitis in Rat

The pathogenesis of inflammatory bowel disease is complex and multifactorial. Studies have led to the current concept that Toll-like receptors represent key mediators of innate host defense in the intestine, and they are involved in maintaining mucosal as well as commensal homeostasis. We studied the possibility of simvastatin and antagonist of receptors of interleukin-1 for pharmacological correction of acute ileitis in rats with a focus on the expression intensity studies of TLR2 TLR4 with lymphocytes of small intestine. Experiments were carried out on male Wistar rats aged 5–7 months (body mass 260–285 g). Rats were divided into four experimental groups: group 1; control, group 2; rats with indomethacin-induced ileitis, group 3; rats given simvastatin (20 mg/kg, for 5 days, subcutaneously), group 4; rats given antagonist of receptors of interleukin-1 (3 mg/kg, for 5 days, subcutaneously). The TLR2 and TLR4 immunopositive lymphocytes were determined using a direct immunofluorescence technique with using a monoclonal rat antibody. We established that development of ileitis was accompanied with the change of amount of TLR2+ and TLR4+ lymphocytes and the density of TLR2, TLR4 in immunopositive cells. Drug administration during the development of experimental pathology was accompanied by changes in the expression of TLR2, TLR4 and their density on lymphocytes. Simvastatin and antagonist of receptors of interleukin-1 seemed to be beneficial in indomethacin-induced rat ileitis model through modulate TLR2 and TLR4 expression with lymphocytes of small intestine